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Abstract
The assessment of blinding in RCTs is rarely performed. Currently most studies that do report data
on evaluation of blinding merely report percentages of correct guessing, not taking into account
correct guessing by chance. Blinding assessment using the blinding index (BI) has never been
performed in a systematic review on studies of major psychiatric disorders. This study is a
systematic review of psychiatric randomized control trials using the BI as a chance-corrected
measurement of blinding, a tool to analyze and understand the patterns of blinding across studies
of major psychiatric disorders with available data. Of 2467 psychiatric RCTs from 2000 to 2010,
66 reported on blinding and 40 studies were found to have enough information on evaluation of
blinding to be analyzed using the BI. The experimental treatment groups had an average BI value
of 0.14 and the control groups had an average BI value of 0.00. The most common BI scenario
was random–random, indicating ideal blinding. A positive correlation between effect size and
more correct guesses was also found. Overall, based on BI values and the most common blinding
scenario, the published articles on major psychiatric disorders from 2000 to 2010, which reported
on blinding assessment for patients, were effectively blinded.
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1. Introduction
Blinding is an important method to reduce bias of many randomized controlled trials (RCT)
whenever relevant and feasible. The ability to achieve its intended goal of an unbiased study
is variable and affected by study methods, study execution, or participants’ (and raters’)
individual beliefs. Blinding assessment can detect potential unblinding which may be
indicative of limited trial validity.
A potential effect of blinding on study outcome has been indicated by various studies. With
regard to subjective outcomes, for example, Wood et al. (2008) have shown smaller effects
in blinded trials than in unblinded studies.
However, it is difficult – if not impossible – to know cause from effect in unblinding.
Whether it is unblinding influencing the effects of a study or the effects of a study resulting
in unblinding. Therefore, interpretation can be difficult and blinding assessment is not
required as per the Consort 2010 guidelines (Schulz et al., 2010) – a change with respect to
the 2001 guidelines (Moher et al., 2001); Consort only recommends the reporting of who
was blinded and how blinding was attempted.
Recent systematic reviews have shown poor reporting of whether and how blinding was
applied throughout RCTs in various fields of research (Rios et al., 2008; Greenfield et al.,
2009; Reveiz et al., 2010; Borg Debono et al., 2012; Ghimire et al., 2012; Péron et al., 2012;
Turner et al., 2012; Baethge et al., 2013). According to Baethge et al. (2013), over the past
decade very few (2.5%) published RCTs on major psychiatric disorders have mentioned
assessment of blinding, and only 54.1% of those reported details of blinding success.
Currently, blinding is measured by asking participants which treatment they believe they
have been assigned (Fergusson et al., 2004; Boutron et al., 2005; Hróbjartsson et al., 2007;
Baethge et al., 2013). In general, such analyses are based on dichotomous answers (e.g.,
verum or placebo), or they include a third option (“don't know”). However, merely reporting
percentages so-derived does not take into account chance agreement. To overcome this
disadvantage blinding indices (BIs) have been developed (James et al., 1996; Bang et al.,
2004).
So far, BI analysis has not been applied to psychiatric RCTs. Blinding could be particularly
critical in psychiatric research because soft or subjective outcomes often serve as study
endpoints. Baethge et al. (2013) looked at the overall percentage of studies performing
assessment of blinding and percentages of participants correct guesses of treatment
allocation groups. This study, based on the work of Baethge et al. (2013), is intended to
apply a BI in order to take chance agreement into account and analyze data in a more
standardized fashion. The BI serves as an objective tool to estimate the percentage of
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excessive correct guesses as a measure of the degree of potential unblinding beyond chance
in a given arm of a study. That is, a chance controlled percentage of participant's correct
guess of the treatment assigned (Bang et al., 2004). Using the BI it is possible to more
rigorously evaluate and interpret the pattern of blinding of trials of psychiatric disorders
(e.g., quantitatively based on BI values and qualitatively based on different blinding
scenarios) and to quantify the extent of blinding in relation with effect size and types of
intervention, i.e. pharmacologic or non-pharmacologic, in a systematic approach.
2. Methods
2.1. Data sources and searches
This study builds upon the systematic review by Baethge et al. (2013) that laid out methods
in detail. In brief, the literature was searched using Medline and PubMed-Central databases.
The search was limited to psychiatric randomized trials in either English or German
published between 2000 and 2010, and it was narrowed with regard to affective disorders
and to schizophrenia.
2.2. Study selection
Screening by Baethge et al. (2013) included full text searches for studies presenting single,
double, or triple blinded RCTs of a psychiatric diagnosis predominantly, but not necessarily
restricted to, schizophrenia and affective disorders as diagnosed by standard international
criteria (DSM-IV or ICD-10).
In the current analysis one author (B.F.) separated the studies selected by Baethge et al.
(2013) based on the reporting of treatment guess data. Independent verification of all
treatment guess data was performed by another author (G.P.). A study was considered to
have reported treatment guess data if participants were surveyed to guess whether they
believed they were receiving Experimental (E) or Control (C) treatment, with or without the
option of “Do not know” (DK), so that data could be tabulated in a 2 × 3 or 2 × 2 format.
When blinding evaluation data was unclear or incomplete, contact with the primary author
by E-mail was attempted twice. Studies with completed data were included, while non-
responding authors and incomplete data were excluded.
If effectiveness of blinding (EOB) was measured multiple times within a study, only the
EOB measured at the end of the study was included. If a study was determined to have two
distinct experimental and control arms with independent EOB results, it was included as two
individual studies. Studies with multiple experimental treatment arms but a single control
arm were included as a single study combining experimental treatment arm results.
2.3. Data extraction
As the primary distinctive requirement of this meta-analysis, the quantity of subject guesses,
E, C, and DK was extracted from each study. Also, it was recorded whether a study's
experimental treatment group was pharmacologic or non-pharmacologic.
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2.4. Data synthesis and analysis
The BI was used to statistically analyze and interpret EOB. BI values can range from 1 to –
1. For example, if all guesses are correct, BI=1; if all guesses are incorrect, BI= −1; and if
50% of guesses are correct and 50% are incorrect then BI=0. Thus the more unblinded a
study is based on participant guesses of treatment group the BI will be closer to −1, while if
more participants are convinced they are in the opposite group the BI will be closer to 1. If
guessing is completely random, as an ideally blinded study should be, BI will equal 0. With
this ability to quantify correct/incorrect guesses within individual treatment arms of a study,
while taking chance agreement into account, it is then possible to compare and further
analyze blinding patterns within and across studies. Nine blinding scenarios have been
proposed to evaluate and interpret the pattern of blinding (Table 1) (Park et al., 2008; Bang
et al., 2010).
We then examined experimental BI (eBI) values, control BI (cBI) values, eBI+cBI from
individual studies, and overall averages of eBIs and cBIs. Using both the calculated eBI and
cBI values, blinding within a study was interpreted based on one of nine blinding scenarios
as shown in Table 1 (Park et al., 2008). In order to separate studies into categories, BI values
of ≥0.2 were considered more correct guesses beyond chance, −0.2<BI<0.2 were random
guesses, and BI values ≤ 0.2 were opposite guesses. [Remark: these values are rules of
thumb rather than definite cutoffs, and they are used here for exploratory classification
purposes only. Also, we used the conventional term ‘unblinded’ for easier communication
(Shapiro, 2003; Bang et al., 2010; Moroz et al., 2013) but it should be understood as “more
correct guesses”.
eBI and cBI were computed from each study, along with 95% confidence intervals (Bang et
al., 2004). For meta-analysis, an inverse-variance weighted average was calculated for both
eBI and cBI. Individual BI values were then divided into two separate groups for
comparison of pharmacologic and non-pharmacologic interventions. In order to use a single
value for a study's overall EOB, eBI+cBI was also calculated as eBI+cBI≅0 can capture two
relatively common ideal blinding scenarios where eBI≅0 and cBI≅0 (i.e., random guess in
both arms) or eBI≅ cBI⪢0 (i.e., participants in both groups tend to guess they received
active treatment). In congruence with parameters set for individual BI values, an eBI+cBI
value of Z0.4 and r 0.4 was considered to have blinding that may call for some attention or
action (e.g., secondary analysis accounting for blinding issues, providing lessons or caveats
for future trials).
In addition, BI values were correlated with effect size, where effect sizes were measured by
Cohen's d (Hedges and Olkin, 1985). Effect size values were those that were used in the
meta-analysis by Baethge et al. (2013).
3. Results
3.1. Data search
Based on the original search criteria from Baethge et al. 3732 studies were found on the
initial search, but 1265 were excluded based on search criteria. Of the remaining 2467
studies that underwent full-text search, 61 were reported to contain information on blinding
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assessment. Five additional studies were found by searching the reference lists of the 61
articles retrieved (Baethge et al., 2013). Of these 66 studies, 37 reported data on subjects'
guesses as to which treatment they had received. After contacting the remaining primary
authors twice, seven authors responded; two submitted the necessary data to include their
studies.
One study (Holroyd, 2006) reported data for two distinct experimental and control arms with
independent EOB results and was included as two separate studies. Four studies were found
to have multiple experimental treatment arms with a single control arm and were included as
a single study combining experimental treatment arms (Fitzgerald, 2003; Hall, 2002;
Morely, 2006; Narushima, 2002). A total of 40 studies with 1907 patients were included in
this meta-analysis (Fig. 1).
3.2. Blinding index calculations
BI values (point and interval estimates), including eBI and cBI, and effect size values
computed from all 40 studies are presented in Table 2. The trends of BI values for
experimental and control groups are plotted in Fig. 2. The 40 experimental treatment groups
had an (inverse-variance weighted) average of 0.14, while the 40 control groups had an
average of 0.00. While experimental treatment groups tend to have random guessing, control
groups more often have random guessing. Comparisons of eBI with effect size (measured by
Cohen's d) and eBI+cBI with effect size are visualized in Fig. 3.
Using the nine blinding scenarios based on the BI as shown in Table 1,0 27.5% (11/40) of
studies were well blinded. On the other hand, including blinding scenarios and eBI + cBI
values, 22.5% (9/40) possibly had problematic blinding. The remaining 50% (20/40) are
included in less certain scenarios that cannot be considered either well or poorly blinded;
however, they can still be interpreted for better understanding by the blinding scenarios. The
largest groups in this ‘gray’ area are random-unblinded (15%), unblinded-opposite (15%),
and unblinded-random (17.5%) for experimental-control.
We repeated the analyses for pharmacologic vs. nonpharmacologic interventions. The
pharmacologic experimental treatment groups had an average BI of 0.18, while the
nonpharmacologic experimental treatment groups had an average BI of 0.00. In contrast, the
pharmacologic control treatment groups had an average BI of −0.02, while the non-
pharmacologic control treatment groups had an average BI of 0.05. When using the nine
blinding scenarios to evaluate pharmacologic and nonpharmacologic studies, 28% (9/32) of
pharmacologic studies had acceptable blinding. Similarly, 25% (2/8) of non-pharmacologic
studies had acceptable blinding.
4. Discussion
After the analysis of the 40 included studies with analyzable data, the overall blinding
scenario/pattern was random in the experimental treatment group and random in the control
group. This leads us to believe that overall, published articles on major psychiatric disorders
from 2000 to 2010, which reported on blinding assessment for patients, were effectively
blinded. Further supporting this idea, the most common blinding scenario was also random–
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random (ideal from the scientific perspective), comprising of 27.5% of all studies included,
as compared to 22.5% of studies having possibly problematic blinding. These figures
support the finding of successful blinding in this group of studies as stated in Baethge et al.'s
(2013) initial report. In comparison, a recent study evaluating the EOB using the BI in
acupuncture studies found the overall blinding scenario as well as most common scenario to
be unblinded-opposite, e.g., most participants thinking they were receiving experimental
treatment regardless of their actual group (Moroz et al., 2013). Trial participants in
psychiatric studies may have a different pattern of expectation. An average cBI of 0.00 lends
support to this assumption.
Three blinding scenarios that cannot be considered either well or poorly blinded contain the
majority of studies comprising this group. The first being random in the experimental arm
and unblinded in the control arm. An interpretation could be that there was little treatment
effect to influence guessing in the experimental arm and there was an inefficient control,
also with no treatment effect, influencing guesses. The second scenario is more correct
guesses in the experimental arm and more incorrect guesses in the control arm. It is possible
that people have ‘wishful thinking’, hoping/believing the treatment they received is real
treatment. This could also be seen as a strong placebo effect. In the third scenario the
experimental arm is unblinded and the control arm is random. A possible explanation is that
in the presence of treatment effect the experimental group becomes unblinded, while the
control is successful in maintaining random guesses.
Of the 9 studies included in blinding scenarios that possibly have problematic blinding, 4 of
them have eBI + cBI values that are ≤ 0.4. Two of those studies have cBIs that are very large
negative values bringing the eBI+cBI into the possibly problematic scenario (Fitzgerald,
2005; Koran, 2009). It is possible that in these studies their controls actually have large
treatment effects and were not inert controls. In the other two studies both cBIs and eBIs
were large negative values (Hypericum Depression Trial Study Group, 2002; Frangou,
2006). This is an interesting scenario since patients in both arms appear to be convinced they
are in the opposite group, which is expected to be rare in practice.
The overall average for control arms showed excellent blinding results with a perfect BI of
0.00. The experimental arm average was still within a reasonable 0.14 of a perfect BI value.
When effect size is compared to eBI, we observed a positive correlation of r = 0.28 between
the two (Fig. 3a). It is possible that effective treatment leads to increased unblinding, which
is natural or even ideal in some settings. There are other possibilities for increased
unblinding including side effects of treatment and accidental unmasking, which could then
lead to a falsely increased effect size so that bi-directionality is possible. This is also seen
when effect size is compared to the overall combined BI value of eBI+cBI. When comparing
effect size to eBI + cBI there is a positive correlation (r=0.4), but there is also a separation
between two groupings of effect size values. As eBI + cBI values increase from 0.14 to 0.19
there appears to be an increase in the overall trend of effect size (Fig. 3b). One possibility is
that as the BI value approaches approximately 0.2 there could be enough unblinding to cross
a threshold artificially inflating effect size, or vice versa. Similar findings have been found
in other studies showing that even if blinding is attempted but is then unsuccessful, it can
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lead to overestimation of treatment effect (Jeong et al., 2013), though it is difficult to know
cause from effect in unblinding.
The division into pharmacologic and non-pharmacologic studies further narrows the window
of excellently blinded and well-blinded results. The pharmacologic control, non-
pharmacologic experimental, and non-pharmacologic control arms were all excellently
blinded, having BI absolute values less than or equal to 0.05. It is interesting to note the
pharmacologic experimental treatment group with a BI of 0.18. This value is still within a
cutoff of 0.2, but is closer to the cutoff. This could be due to greater side effects or
noticeable improvements in patients taking pharmacological treatment. We tend to believe,
however, that it is easier to blind a standard pharmacologic trial than a study involving
psychotherapy. A patient usually knows whether or not he/she sat down with a therapist and
may also be aware of the principles of the psychotherapy under study. The other type of
nonpharmacologic intervention included in the studies used was transcranial magnetic
stimulation. This intervention uses sham controls, which has the capability for successful
blinding. The results of this current meta-analysis show the potential for successful blinding
of non-pharmacologic interventions, but validation and elucidation are warranted.
Although we use the conventionally accepted term, unblinding, it has to be acknowledged
that it is impossible to estimate blinding or unblinding. One can only know if the answered
guess is correct or not (Roy, 2012). While this review is more quantitative and systematic in
evaluating blinding methods for major psychiatric studies than in the past, it too has its
limitations. With finite resources, Baethge et al. limited their literature search to Medline as
the single most important literature database in Medicine, particularly with regard to
pharmacopsychiatry. While it is likely that expanding the search to EMBASE or PsycInfo
would have resulted in a limited number of additional RCTs. Also, it is conceivable that
publication bias or selective reporting plays a role in explaining the results (Phillips, 2004).
Our sample size of 40 studies only represents 1.6% of the studies meeting our initial search
criteria. It is possible that the other 98.4% either chose not to evaluate blinding, selectively
withheld blinding assessment data, or did not know/understand an accepted analytic method
to evaluate and interpret blinding. Further valuable and representative data may have been
found if blinding assessment was more widely performed (Rossner et al., 2007). As this
review shows a feasible method for blinding evaluation, future studies in psychiatric
research may follow this blueprint on an individual basis for the evaluation of blinding.
Reporting of honest and unbiased data is strongly called for. Even in our report of
voluntarily reporting studies more than one fifth showed some indication of possibly
problematic blinding. There was also a small and unbalanced sample size in subgroup
analyses (e.g., when comparing pharmacologic and non-pharmacologic treatments).
This systematic review's approach is intended to demonstrate the feasibility of BI evaluation
of psychiatric RCTs and meant as an empirical effort for the evaluation of blinding, where
blinding data are not commonly reported/available but some did provide sufficient data (so
that we can format data in standardized fashion), which allow statistical analyses. This
review could strengthen the blinding analysis in psychiatric RCTs and provide new insights
on blinding patterns.
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Experimental (a:upper) and Control (b:lower) BI values with confidence intervals.
Confidence intervals (CIs) are 95% CIs, unadjusted for multiple testing. Those with missing
error bars have values that exceed those shown in the scale of these figures.
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Experimental BI values (a:upper) and the sum of Experimental and Control BI values
(b:lower) overlaid with Effect sizes. Higher eBI+cBI values indicate more excessive
proportion of correct guesses while controlling for chance and ‘wishful thinking’. Effect
Sizes are measured by Cohen's d.
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Table 1
Blinding Scenarios (eBI, cBI) in 40 trials.
Experimental arm (Verum) Control arm (Sham) Possible blinding and clinical effectiveness interpretations Trials number (%)
Random guess Random guess Ideal 11 (27.5)
Random guess Opposite guess Rare 2 (5)
Random guess Unblinded Possibly little treatment effect and completely no effect in
control arm
6 (15)
Unblinded Unblinded Possibly problematic, strong treatment effect in experimental
arm and no treatment effect in control arm (e.g. patients tend
to know what to expect)
2 (5)
Unblinded Opposite guess Possible that patients tend to have wishful thinking, weak
treatment and strong placebo effect, or any treatment
administered is perceived as real treatment
6 (15)
Unblinded Random guess Possible treatment effect in experimental arm and no treatment
effect in control arm (e.g. patients do not know what to expect
in the absence of treatment)
7 (17.5)
Opposite guess Opposite guess Rare 2 (5)
Opposite guess Random guess Rare 2 (5)
Opposite guess Unblinded No treatment effect at all, or patients may have low
expectations
2 (5)
These values are rules of thumb (based on 0.2 cutoff) rather than definite cutoffs, and used here only for exploratory classification purposes (Bang
et al., 2010).
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Table 2
BI values and effect sizes.
eBI [CI 95%] cBI [CI 95%] Effect size Exper. type
Frangou (2006) –0.55 [–1.33 to 0.23] –0.48 [–1.32 to 0.36] 0.34 P
HDTSG (2002) –0.42 [–1.0 to 0.16] –0.38 [–0.93 to 0.17] –0.18 P
Schutter (2009) –0.38 [–1.21 to 0.45] 0.13 [–0.23 to 0.49] 0.19 NP
Heinrich (2005) –0.27 [–0.94 to 0.4] 0.17 [–0.22 to 0.56] N.A. P
Carlson (2007) –0.38[–0.96 to 0.2] 0.31 [0.22–0.4] –0.19 P
Rogers (2008) –0.21 [–0.61 to 0.19] 0.34 [0.19–0.49] 0.16 P
Koran (2009) –0.17 [–0.89 to 0.55] –0.5 [–1.49 to 0.49] –0.17 P
Burke (2000) 0[–0.33 to 0.33] –0.33 [–1.14 to 0.48] N.A. P
Ahluwalia (2002) 0.16 [0.12–0.2] –0.17 [–0.48 to 0.12] 0.20 P
Simon (2004) 0.17 [0.17–0.17] –0.07 [–0.32 to 0.18] –0.11 P
Lemoine (2000) 0[–0.36 to 0.36] 0 [–0.36 to 0.36] N.A. P
Holroyd (2006) 0.16 [0.03–0.29] 0.03 [–0.27 to 0.33] 0.80 P
Merry (2004) –0.01 [–0.11 to 0.09] 0.04 [–0.04 to 0.12] 0.09 NP
Posternak (2008) 0.05 [–0.21 to 0.31] 0.04 [–0.11 to 0.19] 0.18 P
van de Rest (2008) 0.03 [–0.03 to 0.09] 0.11 [0.1–0.12] N.A. P
Zhang (2009) 0.03 [–0.14 to 0.2] 0.11 [0.01–0.21] 0.06 P
Narushima (2002) 0.19 [0.04–0.34] 0.13 [–0.23 to 0.49] 0.66 P
Soares (2001) 0[–0.4 to 0.4] 0.14 [–0.14 to 0.42] N.A. P
Loo (2010) –0.12 [–0.63 to 0.39] 0.18 [–0.11 to 0.47] 0.23 NP
Fitzgerald (2003) –0.15 [–0.61 to 0.31] 0.2 [–0.03 to 0.43] 0.53 NP
Kumari (2006) 0.09 [–0.41 to 0.59] 0.2 [–0.21 to 0.61] 0.37 P
Loo (2007) 0.16 [–0.02 to 0.34] 0.21 [0.14–0.28] 0.38 NP
Hughes (2000) –0.06 [0.46 to 0.34] 0.29 [0.22–0.36] 0.45 P
Hoffman (2005) 0.08 [–0.23 to 0.39] 0.43 [0.39–0.47] 0.77 NP
Lucas (2009) 0.11 [–0.15 to 0.37] 0.44 [0.29–0.59] 0.00 P
Fitzgerald (2005) 0.29 [0.13–0.45] –0.69 [–1.77 to 0.39] 0.47 NP
Mischoulon (2010) 0.43 [0.39–0.47] –0.65 [–1.66 to 0.36] –0.11 P
Calabrese (2008) 0.25 [0.11–0.39] –0.41 [–1.19 to 0.37] 0.29 P
Hall (2002) 0.75 [0.12–1.38] –0.36 [–0.95 to 0.23] 0.18 P
Hernandez-Avila (2004) 1[1.0–1.0] –0.33 [–1.14 to 0.48] 0.44 P
Holroyd (2006) 0.53 [0.24–0.82] –0.21 [–0.73 to 0.31] 0.80 P
Killen (2000) 0.24 [0.16–0.32] –0.19 [–0.6 to 0.22] 0.00 P
Blumenthal (2007) 0.4 [0.2–0.6] –0.12 [–0.48 to 0.24] 0.29 P
Rabkin (2006) 0.28 [0.23–0.33] –0.09 [–0.43 to 0.25] 0.52 P
Atkinson (2007) 0.4 [0.23–0.57] –0.05 [–0.52 to 0.42] 0.04 P
Fitzgerald (2006) 0.2 [0.02–0.38] 0 [–0.42 to 0.42] 0.9 NP
Morley (2006) 0.27 [0.21–0.33] 0.05 [–0.21 to 0.31] 0.01 P
Devanand (2005) 0.25 [0.16–0.34] 0.08 [–0.16 to 0.32] 0.18 P
Grenyer (2007) 0.8 [0.19–1.41] 0.3 [0.28–0.32] N.A. P
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eBI [CI 95%] cBI [CI 95%] Effect size Exper. type
Parker (2006) 0.5 [0.5–0.5] 0.5 [0.5–0.5] 0.7 P
Experimental arm BI value (eBI), Control arm BI value (cBI), Pharmacologic (P), Non-Pharmacologic (NP), Hypericum Depression Trial Study
Group (HDTSG). BI and effect sizewere measured for experimental and control arms of HDTSG not including the active comparator. Effect Size
measured by Cohen's d. N.A.: Not available because data in original papers were not sufficient to calculate effect size using standard methods. See
Supplementary table for individual study characteristics.
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